Travere Therapeutics Q4 Earnings Call Highlights

Core Insights - Travere Therapeutics reported record demand for FILSPARI in the fourth quarter, with 908 new patient starts, indicating growing physician confidence and increased adoption among both new and established prescribers [2][4][6] - The company highlighted strong revenue growth for FILSPARI, generating $103.3 million in Q4 and $322 million for the full year 2025, despite the entry of additional therapies into the market [6][17] - The FDA's review timeline for FILSPARI's supplemental indication in focal segmental glomerulosclerosis (FSGS) has been extended to April 13, 2026, due to a major amendment [6][8] Demand and Adoption - The demand for FILSPARI is attributed to its unique profile as a once-daily oral, non-immunosuppressive therapy, along with simplified monitoring requirements and alignment with KDIGO guidelines [1][4] - Adoption is particularly increasing among IgAN patients with proteinuria levels below 1.5 grams per gram, consistent with guidelines advocating for earlier intervention [1][6] Financial Performance - For Q4 2025, Travere reported U.S. net product sales of $126.6 million, with FILSPARI contributing significantly to this figure [17] - The company achieved a net income of $2.7 million in Q4 2025, a significant improvement from a net loss of $60.3 million in the same quarter the previous year [18] Research and Development - Travere has resumed global site activation for the pivotal Phase 3 HARMONY study of pegtibatinase in classical homocystinuria (HCU), with dosing expected to restart soon [5][16] - The company remains confident in FILSPARI's clinical profile for FSGS, supported by strong results from Phase 2 and Phase 3 studies [11][12] Market Outlook - Management anticipates continued growth in net product sales for FILSPARI, with gross-to-net discounts expected to increase to the mid-20% range for 2026 [20] - Operating expenses are projected to grow moderately in 2026, driven by the execution of ongoing studies and commercial investments [20]